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Abstract
Background: Multidrug-resistant (MDR) organisms have been increasingly reported at hospital admission.
Recognising the magnitude, trend and predictors for MDR organisms in community-onset bloodstream infections
(COBSI) is crucial for guiding empiric antibiotic prescribing.
Methods: Positive blood culture isolates recovered from patients presenting to the emergency department during
a ten-year period (1st Jan 2002-31st Dec 2011) were assessed. Trend analyses of MDR organisms were performed.
Risk factors for COBSI caused by an MDR organism and predictors for 30-day mortality were also determined.
Results: A total of 1721 positive blood culture isolates were identified during the study period with a yearly
incidence of 30-43 isolates/10 000 ED presentations. The proportion of MDR Escherichia coli causing COBSI
increased from 9%-26% (P < 0.001), whilst methicillin-resistant Staphylococcus aureus remained at high levels
(20%-30%). A total of 360 patients were included in a matched case-control (1:1) study, and residents in long-term
care facilities (adjusted odds ratio [AOR], 4.9 [95% CI, 2.1-11.6]), home wound care (AOR, 5.5 [95% CI, 1.6-18.7]),
underlying immunosuppression (AOR, 3.5 [95% CI, 1.6-7.7]), recent surgery (AOR, 3.5 [95% CI, 1.1-11.6]), and exposure
to antibiotics within 3 months (AOR, 5.5 [95% CI, 2.8-10.6]) were independently associated with MDR COBSI. High
risk source of COBSI, age and Pitt bacteraemia score were independent predictors for 30-day mortality.
Conclusions: A concerning trend in MDR organisms causing bloodstream infection from the community is
occurring. Risk factors for MDR organisms have been identified to assist in empiric antibiotic prescribing for those
presenting to hospital with sepsis.
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Background
Antimicrobial resistance in common bacterial pathogens
causing community-onset infections, including blood-
stream infection (BSI), has increasingly been reported, most
notably methicillin-resistant Staphylococcus aureus (MRSA)
and various multidrug-resistant (MDR) gram-negative
bacilli (GNB) [1,2]. This poses significant challenges to cli-
nicians caring for patients presenting to hospital with sus-
pected sepsis as empiric antibiotic prescribing is often
targeting presumed, antibiotic-susceptible, community or-
ganisms. Identification of risk factors for MDR organisms
in patients presenting from the community with sepsis is
necessary to help optimise patient outcomes and minimise
the use of broad-spectrum antibiotics.
Emergency departments (EDs) serve as an important
interface between community and hospital care; the mi-
crobial ecology is often a combination of community-and
healthcare-associated organisms, the latter being driven by
healthcare re-admissions. Friedman et al. proposed that
healthcare-associated (HCA) bloodstream infection should
be treated with broad-spectrum antibiotics to cover for
MDR organisms [3]. However, the broad nature of the
HCA risk factors may lead to unnecessary use of last-line
antibiotics, especially in settings with a low prevalence of
* Correspondence: anton.peleg@monash.edu
†Equal contributors
3Department of Microbiology, School of Biological Sciences, Monash
University, Building 76, Wellington Road, Melbourne, Victoria 3800, Australia
4Department of Infectious Diseases, Alfred Health, Melbourne, Victoria,
Australia
Full list of author information is available at the end of the article
© 2014 Lim et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Lim et al. BMC Infectious Diseases 2014, 14:126
http://www.biomedcentral.com/1471-2334/14/126
MDR organisms [4]. Several studies have worked towards
refining predictors for MDR organisms in community-
onset pneumonia [5-7]; similar work to predict MDR
organisms in community-onset bloodstream infections
(COBSI) remains scant.
To date, the prevalence and trend of major MDR or-
ganisms causing COBSI remain poorly understood. Fur-
thermore, data on risk factors and outcomes associated
with COBSI due to MDR organisms are limited. Accord-
ingly, we explored the longitudinal trend, risk factors
and clinical outcomes associated with MDR organisms
causing COBSI in a tertiary care institution. These data
are critical in devising the most effective empiric antibi-
otics to maximise patient outcomes.
Methods
Study design and population
We performed an observational series and a matched
case-control study at The Alfred, a tertiary referral hos-
pital in metropolitan Melbourne, Australia. We studied
all cases of bloodstream infection presenting from the
community to The Alfred’s ED. This ED provides specia-
lised state-wide services for major emergency and
trauma, burns, heart and lung transplantation, cystic fi-
brosis and neurosurgery patients. It attends to over 55
000 patients annually. The study was approved by the
human research ethics committees of The Alfred and
Monash University.
Data collection and definitions
Data collection was broadly divided into two parts:
i) Prevalence and temporal trends of MDR organisms
Positive clinical isolates recovered from blood
cultures of patients within 48 hours of ED admission
during a ten-year period (1st January 2002 and 31st
December 2011) were examined from a microbiol-
ogy laboratory database. Repeat cultures from an
individual patient growing the same organism within
14 days, cultures reported as normal flora or prob-
able contaminants (eg. coagulase-negative staphylo-
cocci from a single blood culture bottle), and clinical
specimens from patients aged < 18 years, were ex-
cluded. Species identification and antimicrobial sus-
ceptibility testing were performed using an automated
system (Vitek®; bioMérieux). For the majority of the
study period (Jan 2002-Jun 2010), susceptibility break-
points were based on the British Society for Anti-
microbial Chemotherapy (BSAC) guidelines [8]. These
were changed to the European Committee on Anti-
microbial Susceptibility Testing (EUCAST) guidelines
from July of 2010 [9]. We observed no change in the
proportion of resistant isolates at the time of the
change in breakpoint definitions.
The temporal trends of MDR GNB, MRSA, and
vancomycin-resistant enterococci (VRE) were
assessed. MDR was defined as being non-susceptible
to at least three different classes of antimicrobial
agents, as described elsewhere [10,11]. For Entero-
bacteriaceae, seven classes of antimicrobials were
assessed, (i) extended-spectrum penicillins or first-
generation cephalosporins, (ii) β-lactam/β-lactamase
inhibitor combinations, (iii) extended-spectrum ceph-
alosporins, (iv) carbapenems, (v) trimethoprim/sulfa-
methoxazole, (vi) aminoglycosides, and (vii)
quinolones. For non-fermenting GNB, antimicrobials
were divided into five classes, (i) antipseudomonal
penicillins, (ii) antipseudomonal cephalosporins,
(iii) carbapenems, (iv) aminoglycosides, and (v)
quinolones.
Multi-resistant MRSA was defined as MRSA
resistant to three or more of the following
antibiotics: erythromycin, ciprofloxacin, gentamicin,
trimethoprim/sulfamethoxazole, tetracycline,
rifampicin, fusidic acid and vancomycin [12]. The
EMRSA-15-like strain was defined as MRSA resist-
ant to ciprofloxacin +/- erythromycin only [12]. All
other MRSA were non-multi-resistant MRSA. For
the Streptococcus pneumoniae strains, the suscepti-
bility interpretation was based on non-central
nervous system breakpoints.
ii) Risk factors and outcomes associated with MDR
COBSI
A matched case-control study was subsequently
conducted for risk factor analysis. A case was de-
fined as an adult (≥ 18 years) with COBSI (organism
isolated from ≥ 1 blood culture within 48 hours of
ED admission) due to a MDR organism. Only the
first admission with COBSI due to a MDR organism
was included in the analysis. Control patients were
adults with COBSI caused by non-MDR organisms
matched for the genus of the causative organism
and the date of ED admission (± 1 year). If more
than one control was identified, the control patient
with the ED admission date closest to the case
patient was chosen. Cases of polymicrobial bacter-
aemia, and patients who were directly transferred
from other hospitals with a hospital stay > 48 hours
were excluded.
Information on patient demographics, sources of
BSI, co-morbidities, recent bacterial infection and
antibiotic use, invasive instrumentation in the pre-
ceding 48 hours, recent surgery, underlying im-
munosuppression, and the presence of healthcare-
associated risk factors were reviewed. Sources of BSI
were divided into low risk sources including urinary,
skin and soft-tissue, and catheter-related, and high
risk sources including respiratory, intra-abdominal,
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bone and joint, cardiovascular or unidentified [13].
Co-morbidities were quantified using the Charlson
comorbidity index [14]. Presence of underlying
immunosuppression was defined as the presence
of neutropenia (absolute neutrophil count of
< 500/mm3), concurrent use of high dose oral corti-
costeroids (at least 10 mg of prednisolone or equiva-
lent for minimum of 30 days) or long-term use of
immunosuppressive agents (e.g. cyclosporine), active
chemotherapy for malignancy, metastatic cancer, or
acquired immunodeficiency syndrome. Healthcare-
associated (HCA) BSI was defined according to
Friedman et al. [3]. This included patients who had
been hospitalised in an acute care hospital for ≥
2 days in the preceding 90 days, residents of a nurs-
ing home or long-term care facility (LTCF), patients
who received home intravenous (IV) therapy,
specialised wound care, and those who underwent
chronic haemodialysis or IV chemotherapy in the
preceding 30 days.
Information related to clinical presentation,
management and outcomes of BSI was also
collected, including severity of BSI according to the
Pitt bacteraemia score [points assigned to specific
clinical observations as (1) oral temperature of
35.1°C-36.0°C or 39.0°C-39.9°C scores 1 point, and a
temperature of either ≤35°C or ≥40°C scores 2
points; (2) systolic blood pressure < 90 mm Hg for
>1 hour despite adequate fluid resuscitation, receipt
of vasopressors, and/or receipt of mechanical
ventilation score 2 points each; (3) cardiac arrest
scores 4 points; and (4) altered mental status scores
1 point for disorientation, 2 points for stupor, and 4
points for comatose] [1], presence of severe sepsis or
septic shock, types and duration of empiric
antibiotic therapy, length of hospital stay and
mortality within 30 days of COBSI. Empirical
antibiotic therapy was considered active when an
antibiotic was given during the first 48 hours that
had in vitro activity against the causative organism.
Statistical analysis
Microbiological data were available from 2002 and de-
nominator data on the number of ED presentations per
year were available from 2004 onwards. A rate was cal-
culated based on the number of isolates per 10 000 ED
presentations per year. Bi-yearly trends in distribution of
major organisms and antimicrobial resistance patterns
were assessed using the chi-squared test for trend or lin-
ear regression.
Risk factor analysis was performed using conditional lo-
gistic regression analyses, firstly by univariate, followed by
multivariate analysis. Variables with a P < 0.1 on univariate
analysis were eligible for entry into the multivariable
model. The variables of ‘invasive instrument in-situ’,
‘underlying immunosuppression’ and ‘prior exposure to
antibiotic’ were considered for inclusion in the multi-
variable model as binary variables, ignoring constituent
variables within the categories. For correlated variables
(pairwise correlation coefficient > 0.7), only one of the
covariates was selected for inclusion into the candidate
models on the basis of the strength of association. Inde-
pendent variables in the final multivariable model were
selected using a stepwise forward process. Model fit was
assessed against the number of variables used, quanti-
fied using the Akaike information criterion to prevent
overfitting. Risk factor analysis for COBSI caused by any
MDR organism was performed first followed by a risk
factor analysis for specific MDR organisms (MDR GNB
and MRSA).
In addition, categorical and continuous variables asso-
ciated with 30-day all cause mortality were compared
between the survival and non-survival groups using uni-
variate and then multivariate logistic regression analyses.
All tests were 2-tailed, and P-values of < 0.05 were con-
sidered statistically significant. Data analyses were per-
formed using IBM SPSS Statistics version 20 (IBM, New
York, USA).
Results
Temporal trend of MDR organisms causing COBSI
A total of 1721 positive blood culture isolates were identi-
fied over a 10-year period from patients presenting to the
ED. From 2004 onwards, there was a yearly incidence of
30-43 BSI per 10 000 ED presentations (Table 1). Overall,
gram-negative organisms (n = 941, 55%) predominated
(Table 1). When adjusted for the number of ED presen-
tations over time, the yearly incidence rate of gram-
positive isolates declined over time (P = 0.02 for trend),
whilst gram-negative isolates remained relatively con-
stant (P > 0.05 for trend).
The proportion of MDR organisms according to genus
is shown in Figure 1. Overall, Escherichia coli was the
most common causative gram-negative organism. The
proportion of MDR E. coli (n = 82) increased signifi-
cantly during the study period from 9% (2002-2003) to
26% (2010-2011) (P < 0.001 for trend). Increasing resist-
ance to important first-line agents was also observed
from years 2002-2003 to 2010-2011; ceftriaxone (1% to
6%, P < 0.01), gentamicin (1% to 12%, P < 0.001) and
ciprofloxacin (3% to 22%, P < 0.01). In contrast, the inci-
dence of MDR Klebsiella spp. (n = 11) and other Entero-
bacteriaceae (n = 20) did not show a significant increase
over time; however this may be partly explained by the
small number of isolates. As expected, BSI caused by
non-fermenting GNB were less common; however there
were still 51 and 12 cases of Pseudomonas aeruginosa
and Acinetobacter spp. in COBSI, respectively. MDR
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cases were also observed (2/51, [4%] for P. aeruginosa
and 3/12, [25%] for Acinetobacter spp.).
S. aureus was the most common gram-positive organ-
ism causing COBSI (n = 206, 26%), with a stable yet high
proportion of MRSA over time of 20%-30%. The majority
of MRSA were of a multi-resistant phenotype (n = 41
[57%]), followed by EMRSA-15-like strains (n = 16 [22%])
and then non-multi-resistant strains (n = 15 [21%]). Over
the 10 years, four VRE in COBSI were identified. About
10% of Streptococcus pneumoniae blood culture isolates
(n = 104) were non-susceptible to penicillin; none of these
were resistant to ceftriaxone.
Risk factors for COBSI due to MDR organisms
There were 194 MDR blood culture isolates identified from
2002-2011. Fourteen isolates were excluded; polymicrobial






















isolates per 10 000
ED presentation
2002 - 156 - 67 - 89 -
2003 - 199 - 107 - 92 -
2004 37765 152 40.3 81 21.5 71 18.8
2005 41912 153 36.5 84 20.0 69 16.5
2006 44417 189 42.6 109 24.5 80 18.0
2007 46979 192 40.9 100 21.3 92 19.6
2008 47356 183 38.6 103 21.8 80 16.9
2009 50155 156 31.1 90 17.9 66 13.2
2010 52985 161 30.4 97 18.3 64 12.1
2011 56120 180 32.1 103 18.4 77 13.7
Total 1721 941 780
NOTE. Data on the number of ED presentations was available from 2004.
Figure 1 The proportion of MDR organisms versus non-MDR organisms in positive blood culture isolates, according to genus. ‘Others’
in the figure refers to other Enterobacteriaceae with ≥ 10 blood isolates during study period (ie. Proteus, Enterobacter, Citrobacter and Serratia spp.).
MDR organisms in S. aureus refers to MRSA whilst in Enterococcus refers to VRE.
Lim et al. BMC Infectious Diseases 2014, 14:126 Page 4 of 9
http://www.biomedcentral.com/1471-2334/14/126
BSI (n = 7), multiple BSI episodes in the same patient (n =
3), direct transfer from other hospital (n = 1) and incom-
plete/missing medical histories (n = 3). Accordingly, 180
case patients were included, with 109 MDR GNB (com-
prised of E. coli [n = 79], Klebsiella spp. [n = 8], other
Enterobacteriaceae [n = 17], P. aeruginosa [n = 2] and
Acinetobacter spp. [n = 3]) and 67 MRSA in the sub-
group analyses.
The characteristics of case and control patients are
shown in Table 2. Sources of COBSI due to MDR organ-
isms composed primarily of urinary sites (n = 60, 33%)
and unidentified sources (n = 53, 29%), followed by
Table 2 Patient characteristics and risk factor analysis for community-onset bloodstream infection caused by a MDR
organism
Risk factors Cases Controls Univariate analysis Multivariate analysis
(n = 180) (n = 180) OR (95% CI) P value AOR (95% CI) P value
Age, mean (SD), years 64.1 (19.4) 65.0 (20.4) 1.00 (0.99-1.01) 0.7
Female, no (%) 69 (38.3) 74 (41.1) 0.94 (0.75-1.18) 0.59
Source of BSI, low riskb, no (%) 94 (52.2) 83 (46.1) 1.32 (0.85-2.03) 0.22
Invasive device in-situ, no (%) 55 (30.6) 21 (11.7) 3.62 (1.96-6.68) <0.001a
Indwelling catheter 25 (13.9) 8 (4.4) 3.43 (1.48-7.96) <0.01
Vascular catheter 27 (15.0) 12 (6.7) 2.67 (1.24-5.74) 0.01
Percutaneous feeding tube 7 (3.9) 1 (0.6) 7.00 (0.86-56.89) 0.07
Friedman et al. HCA risk factors, no (%) 148 (82.2) 72 (40.0) 6.81 (3.81-12.19) <0.001
Prior hospitalisation (≥2d) last 90d 113 (62.8) 44 (24.4) 4.62 (2.81-7.58) <0.001a
Residence in long-term care facilities 51 (28.3) 23 (12.8) 2.79 (1.57-4.94) <0.001a 4.94 (2.11-11.59) <0.001
Home intravenous therapy last 30d 27 (15.0) 9 (5.0) 2.89 (1.35-6.17) 0.006a
Home wound care last 30d 35 (19.4) 5 (2.8) 6.96 (2.72-17.80) <0.001a 5.48 (1.61-18.69) <0.01
Haemodialysis last 30d 5 (2.8) 12 (6.7) 0.42 (0.15-1.18) 0.100
Intravenous chemotherapy last 30d 32 (17.8) 15 (8.3) 2.31 (1.20-4.42) 0.012a
Underlying immunosuppression, no (%) 77 (42.8) 35 (19.4) 3.73 (2.11-6.60) <0.001a 3.49 (1.58-7.71) <0.01
Neutropenia 23 (12.8) 11 (6.1) 2.20 (1.04-4.65) 0.04
Active or metastatic cancer 45 (25.0) 25 (13.9) 2.11 (1.21-3.70) 0.01
Concurrent immunosuppressant agents 31 (17.2) 8 (4.4) 4.14 (1.82-9.46) <0.01
Surgery last 30d, no (%) 38 (21.1) 9 (5.0) 6.60 (2.58-16.91) <0.001a 3.52 (1.06-11.64) 0.04
Bacterial infection last 3mo, no (%) 99 (55.0) 34 (18.9) 5.32 (3.06-9.23) <0.001c
Presence of BSI last 3mo, no (%) 36 (20.0) 7 (3.9) 6.80 (2.66-17.39) <0.001a
Prior antibiotic exposure last 3mo, no (%) 127 (70.6) 39 (21.7) 7.73 (4.34-13.78) <0.001a 5.49 (2.84-10.61) <0.001
Prolonged exposure >14d 78 (43.3) 27 (15.0) 4.38 (2.50-7.68) <0.001
Fluoroquinolone 43 (23.9) 9 (5.0) 5.86 (2.63-13.06) <0.001
Extended-spectrum cephalosporin 32 (17.8) 5 (2.8) 7.95 (2.80-22.55) <0.001
Penicillin + beta lactamase inhibitor 44 (24.4) 15 (8.3) 3.64 (1.87-7.09) <0.001
Vancomycin 27 (15.0) 10 (5.6) 2.78 (1.30-5.95) 0.01
Diabetic mellitus, no (%) 45 (25.0) 28 (15.6) 1.95 (1.12-3.39) 0.018a
Cardiovascular disease, no (%) 50 (27.8) 40 (22.2) 1.36 (0.85-2.16) 0.200
Cerebrovascular disease, no (%) 30 (16.7) 27 (15.0) 1.10 (0.63-1.94) 0.74
Lung disease, no (%) 47 (26.1) 32 (17.8) 1.66 (0.97-2.82) 0.062a
Renal disease, no (%) 25 (13.9) 28 (15.6) 0.89 (0.51-1.54) 0.68
Liver disease, no (%) 21 (11.7) 18 (10.0) 1.20 (0.61-2.38) 0.6
Malignancy, no (%) 71 (39.4) 48 (26.7) 1.71 (1.10-2.66) 0.018a
Charlson co-morbidity index, mean (SD) 3.4 (2.6) 2.0 (2.0) 1.24 (1.13-1.36) <0.001a
NOTE. OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval; SD, standard deviation; BSI, bloodstream infections; HCA, healthcare-associated.
aVariables eligible for inclusion in the multivariate analysis.
bLow risk sites are BSI secondary to urinary, skin & soft tissue and catheter-related sites.
cPairwise correlation >0.7 with prior antibiotic exposure last 3mo.
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catheter-related (n = 18, 10%), skin and soft tissue (n = 16,
9%), bone and joint (n = 13, 7%), intra-abdominal (n = 10,
6%), and respiratory sites (n = 10, 6%). Overall, 82% of the
case patients met the Friedman et al. criteria [3] for HCA
BSI, however 40% of the control patients also had at least
one of these defined risk factors. Multivariable analysis
showed that residents in LTCF, home wound care, under-
lying immunosuppression, recent surgery and prior expos-
ure to antibiotics were independent risk factors for COBSI
caused by a MDR organism (Table 2).
Subgroup analyses for specific risk factors for MDRGNB
and MRSA are shown in Table 3. In addition to being a
resident in a LTCF and prior exposure to antibiotics,
home IV therapy and younger age were also independ-
ently associated with COBSI due to MDR GNB. Seven
of 18 (39%) MDR GNB case patients with an age <
40 years had no identified predisposing risk factors and
all but one were COBSI associated with a urinary
source. On the other hand, hospitalisation in the last
three months, residing in LTCF, receiving home wound
care and underlying immunosuppression were inde-
pendently associated with COBSI caused by MRSA. A
significantly higher proportion of COBSI cases with
MRSA (63/67, 94%) compared to cases with MDR GNB
(81/109, 74%) fulfilled at least one Friedman et al. cri-
teria (P = 0.001).
Clinical management and outcomes of COBSI
Community-onset BSI caused by MDR organisms was
significantly more likely to be treated with inactive em-
pirical antibiotic therapy (42% vs. 1%, P < 0.001). The
median length of hospital stay for those infected with
MDR organisms was 11 days (interquartile range [IQR]
6-20) compared with 9 days (IQR 5-17) (P < 0.05) for
those with non-MDR organisms. The overall 30-day
mortality observed in both groups was 13% (46 / 360),
with 16% (n = 28) in those infected with MDR organisms
as opposed to 10% (n = 18) in non-MDR infections
Table 3 Subgroup analyses of risk factors for community-onset bloodstream infection caused by MDR GNB and MRSA
Variables BSI with MDR GNB, case = 109, control = 109 BSI with MRSA, case = 67, control = 67
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
OR (95% CI) P value AOR (95% CI) P value OR (95% CI) P value AOR (95% CI) P value
Age, years 0.99 (0.97-1.00) 0.045a 0.98 (0.96-1.00) 0.03 1.02 (1.00-1.04) 0.061a
Female 1.05 (0.58-1.91) 0.88 0.66 (0.31-1.41) 0.29
Low risk BSI sourcesb 1.29 (0.73-2.27) 0.39 1.71 (0.83-3.49) 0.15
Invasive device in-situ 3.43 (1.48-7.96) 0.004a 5.50 (1.90-15.96) 0.002a
Indwelling catheter 2.60 (0.93-7.29) 0.07 11.00 (1.42-85.20) 0.02
Vascular catheter 3.25 (1.06-9.97) 0.04 2.50 (0.78-7.97) 0.12
Friedman et al. HCA risk factors 4.90 (2.48-9.67) <0.001 13.17 (4.07-42.59) <0.001
Prior hospitalisation (≥2d) last 90d 4.50 (2.27-8.93) <0.001a 4.75 (2.31-9.75) <0.001a 5.87 (1.37-25.21) 0.02
Residence in long-term care
facilities
2.44 (1.13-5.31) 0.024a 5.56 (1.60-19.34) <0.01 3.78 (1.53-9.33) 0.004a 12.38 (2.45-62.63) <0.01
Home intravenous last 30d 8.00 (1.84-34.79) 0.006a 8.33 (1.52-45.75) 0.02 1.67 (0.61-4.59) 0.32
Home wound care last 30d 1.67 (0.40-6.97) 0.48 13.94 (3.31-58.68) <0.001a 6.74 (1.06-42.70) 0.04
Haemodialysis last 30d 1.50 (0.25-8.98) 0.66 0.22 (0.05-1.03) 0.054a
Intravenous chemotherapy
last 30d
2.86 (1.29-6.43) 0.010a 1.75 (0.51-5.98) 0.37
Underlying immunosuppression 3.09 (1.57-6.10) 0.001a 6.67 (1.98-22.44) 0.002a 7.21 (1.20-43.43) 0.03
Neutropenia 2.57 (1.07-6.16) 0.03 2.00 (0.37-10.92) 0.42
Active or metastatic cancer 2.25 (1.14-4.44) 0.02 1.80 (0.60-5.37) 0.29
Surgery last 30d 6.50 (1.47-28.80) 0.014a 9.50 (2.21-40.79) 0.002a
Presence of BSI last 3mo 6.00 (1.77-20.37) 0.004a 6.50 (1.47-28.80) 0.014a
Prior antibiotic exposure last 3mo 8.29 (3.78-18.15) <0.001a 7.94 (3.36-18.80) <0.001 6.76 (2.87-15.92) <0.001a
Diabetic 1.91 (0.92-3.96) 0.082a 1.75 (0.73-4.17) 0.21
Malignancy 1.81 (1.06-3.08) 0.029a 1.30 (0.57-2.97) 0.53
Charlson co-morbidity index 1.16 (1.04-1.30) 0.007a 1.38 (1.15-1.67) 0.001a
Intravenous drug user, IVDU NA NA 0.07 (0.01-0.51) 0.009a
NOTE. OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval; BSI, bloodstream infections; HCA, healthcare-associated; NA, not applicable.
aVariables eligible for inclusion in the multivariate analysis.
bLow risk sites are BSI secondary to urinary, skin & soft tissue and catheter-related sites.
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(P = 0.127). The prognostic factors for 30-day mortality
are shown in Table 4. Older age, higher Pitt bacteraemia
score, and high risk sources of bacteraemia were inde-
pendent predictors for mortality within 30 days of COBSI.
Community-onset BSI caused by a MDR organism, receipt
of inactive empiric antibiotic therapy and COBSI defined
as HCA BSI were not significant predictors.
Discussion
This study has shown that MDR GNB have joined MRSA
as an important cause of bloodstream infection presenting
from the community, highlighting the evolving challenges
of empiric antibiotic prescribing for severe infections at the
front-line of hospital admission. We identified differences
in risk factors for MDR GNB and MRSA that are in keep-
ing with the changing epidemiology of these organisms.
The increase in MDR GNB was largely attributable to
MDR E. coli, whereas MDR in non-fermenting GNB
remained relatively uncommon. Traditional risk factors for
infection with an MDR organism such as HCA risk factors
proposed by Friedman et al. [3], appeared predictive for
MRSA COBSI but were less predictive for MDR GNB in-
fection. Patients with COBSI due to an MDR organism
were more likely to be prescribed inactive empiric therapy
and were associated with longer hospital stays; nonetheless,
COBSI with an MDR organism was not related to signifi-
cantly higher 30-day mortality.
In the last decade, emergence of MDR GNB at hos-
pital admission has been reported [1,15,16]. The most
recent Australian surveillance data revealed an emerging
trend of MDR E. coli in urinary isolates from the com-
munity, rising from 4.5% in 2008 to 7.2% in 2010 [17].
Apart from the known increase in MDR GNB causing
community urinary tract infections, fewer studies have
focused on the trends in more severe community infec-
tions like bloodstream infection [1]. Our data showed
that a staggering 26% of E. coli bloodstream infection
presenting to ED was MDR. Our standard first-line em-
piric therapy to cover GNB for suspected sepsis is often
an aminoglycoside or a third-generation cephalosporin
[18]; however 6% and 12% of blood culture isolates were
resistant to these agents, respectively. Furthermore, 22%
were resistant to ciprofloxacin. Identifying risk factors to
help determine who should receive broader-spectrum
antibiotics for patients presenting to ED with suspected
BSI is needed.
In contrast to previous studies [16,19], older age was not
shown to be a predictor for acquiring MDR organisms; on
the contrary, older patients were less likely to have a
COBSI with MDR GNB. Our data suggest a potential shift
in the epidemiology of MDR GNB to a younger patient
population, and this was not limited to patients with
underlying medical conditions or predisposing healthcare-
associated risk factors. This trend warrants further investi-
gation into other potential community-acquired risk
factors in this patient group such as travel and close
contacts. A study by Kennedy and Collignon shows that
approximately 50% of Australian travelers returning
from high incidence countries such as India and China
were colonised with drug-resistant E. coli and can re-
main colonised for months [20]. As such, specific ques-
tioning about travel is now recommended for all
patients with presumed infections at ED admission, with
modification of empiric antibiotic prescribing if positive.
Table 4 Predictors of 30-day all-cause mortality among patients with community-onset bloodstream infection




Univariate analysis Multivariate analysis
n = 46 n = 314 OR (95% CI) P value AOR (95% CI) P value
Age, mean (SD), years 74.8 (16.3) 63.1 (19.9) 1.04 (1.02-1.06) <0.001a 1.04 (1.02-1.06) <0.001
Male, no (%) 31 (67.4) 186 (59.2) 1.42 (0.74-2.74) 0.29
Residence in LTCF, no (%) 18 (39.1) 56 (17.8) 2.96 (1.53-5.72) 0.001a
Charlson co-morbidity index, mean (SD) 3.5 (2.2) 2.6 (2.4) 1.15 (1.02-1.30) 0.018a
Acquisition-healthcare associated, no (%) 35 (76.1) 185 (58.9) 2.22 (1.09-4.53) 0.029a
Underlying immunosuppression, no (%) 14 (30.4) 98 (31.2) 0.96 (0.49-1.89) 0.92
High risk BSI sourcesb, no (%) 30 (65.2) 153 (48.7) 1.97 (1.03-3.76) 0.039a 2.30 (1.16-4.57) 0.02
Pitt bacteraemia score, median (IQR) 2 (1-4) 1 (0-2) 1.39 (1.18-1.64) <0.001a 1.36 (1.15-1.61) <0.001
Severe sepsis or septic shock, no (%) 13 (28.3) 38(12.1) 2.86 (1.39-5.91) 0.005c
ICU admission, no (%) 12 (26.1) 51 (16.2) 1.82 (0.88-3.75) 0.11
Bacteraemia due to MDR organisms, no (%) 28 (60.9) 152 (48.4) 1.66 (0.88-3.12) 0.12
Inactive empiric antibiotic, no (%) 16 (34.8) 61 (19.4) 2.21 (1.13-4.31) 0.02a
NOTE. OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval; SD, standard deviation; IQR, interquartile range; LTCF, long-term care facility;
BSI, bloodstream infections; ICU, intensive care unit; MDR, multidrug-resistant.
aVariables eligible for inclusion in the multivariate analysis.
bHigh risk sources refer to BSI secondary to respiratory, gastrointestinal, hepatobiliary, bone and joint, cardiovascular or unidentified sources.
cPairwise correlation >0.7 with Pitt bacteraemia score.
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Due to the retrospective nature of our study, these risk
factors could not be evaluated.
We observed a high rate of community-onset MRSA
bacteraemia at 20%-30% throughout the 10-year study
period. A nationwide surveillance of staphylococcal bacter-
aemia in Australia and New Zealand revealed that MRSA
bacteraemia was no longer confined to hospitals and has
become an issue in the community [2]. The incidence of
MRSA bacteraemia in the ED setting, however, has been
less clear. Rather than being the traditional community
phenotype of MRSA (nmMRSA), the majority of our
MRSA infections (57%) were of a HCA phenotype (multi-
resistant) in patients with healthcare-associated risk factors.
These risk factors appear to be an important guide to add-
ing empiric anti-MRSA cover in those with presumed
staphylococcal bacteraemia.
HCA BSI criteria were initially proposed by Friedman
at el to help clinicians identify patients with a higher risk
of acquiring MDR pathogen [3]. Subsequently, this con-
cept has been consolidated further with the introduction
of the American Thoracic Society and the Infectious
Diseases Society of America guidelines, which suggest
use of broad-spectrum antibiotics for those who meet
the HCA criteria for healthcare-associated pneumonia
[21]. Interestingly, in our study, 40% of those with COBSI
caused by a susceptible organism (72/180) had a HCA risk
factor (only two of these were infected with P. aeruginosa).
This suggests that further studies are required to refine
the risk factors for an infection caused by a MDR organ-
ism presenting to the ED in order to prevent overuse of
broad-spectrum antibiotics.
The impact of antibiotic resistance on treatment and
patient outcomes has varied considerably between stud-
ies [22-24]. One of the most consistent findings however
is that infection with a MDR organism leads to an in-
crease in receipt of inactive empiric antibiotic therapy
[25,26]. Our data showed an association between in-
active empiric therapy and 30-day mortality but this was
not statistically significant after controlling for other
confounders. The adverse consequences of inactive em-
piric therapy on increasing mortality in BSI remain in-
consistent in the literature, especially for gram-negative
bacteria, and depend on the source and severity of
bacteraemia [27,28]. In our study, the high risk source of
COBSI and higher Pitt bacteraemia score were shown to
be independent predictors for mortality. However, severe
sepsis/septic shock were not independent predictors and
this was due to the fact that these covariates were cap-
tured within the Pitt bacteraemia score (correlation coeffi-
cient was > 0.7, Table 4). Although the presence of MDR
organisms in COBSI was not associated with increased
30-day mortality, it was associated with an increase in
length of hospital stay. Importantly, the economic impact
of infections associated with MDR organisms originating
from the community warrants further investigation to fa-
cilitate healthcare resource allocation.
The current study has several limitations. Due to its
retrospective nature, risk factors such as recent travel, his-
tory of colonisation or close contacts with MDR organ-
isms could not be assessed. Furthermore, mechanisms of
resistance such as the presence of extended-spectrum β-
lactamases or carbapenemases were not elucidated. An
automated system (Vitek®) was used for susceptibility test-
ing and therefore exact minimum inhibitory concentra-
tions were not reported. This study was conducted at a
large tertiary ED in southern Australia, and thus the re-
sults may not be generalisable to other EDs with different
patient demographic profiles or clinical burden.
Conclusions
This work has highlighted concerning trends toward
greater antimicrobial resistance in common pathogens
causing COBSI. An ideal model to predict COBSI with
MDR organisms may incorporate a number of clinical fac-
tors (e.g. prior exposure of antibiotics, underlying immu-
nosuppresion), relevant healthcare-associated risk factors,
and possibly organism-specific risk factors (e.g. recent
travel and MDR Enterobacteriaceae). These studies are
essential to assist with the challenges of empiric antibiotic
prescribing for those presenting to hospitals with sus-
pected sepsis.
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